Firm stops trials of obesity drug

Sanofi-Aventis has discontinued all trials of its anti-obesity drug rimonabant (Acomplia), which was suspended by the European Medicines Agency last month.

At the time of the suspension, Sanofi-Aventis said it saw the suspension as temporary and that it hoped ongoing studies would provide additional evidence for the product's safety and benefit in patients with diabetes and cardiovascular disease.

The company has now announced that it has decided to discontinue the ongoing rimonabant clinical development programme in all indications.

The decision has been taken 'in light of recent demands by certain national health authorities', a spokesman said.

'As a result the feasibility of the global clinical development programme has been compromised.'

The EMEA withdrew the European Marketing Authorisation for Acomplia after an assessment of the drug's benefits and risks showed an increased risk of psychiatric disorders patients.

The agency said it believed that these side-effects could not be adequately addressed by risk minimisation measures.

tom.moberly@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Summary of changes to the GP contract 2021/22

Summary of changes to the GP contract 2021/22

The BMA and NHS England have agreed minor changes to the GP contract for 2021/22....

Minor changes agreed to GP contract for 2021/22 amid ongoing pandemic pressure

Minor changes agreed to GP contract for 2021/22 amid ongoing pandemic pressure

Changes to the GP contract for 2021/22 will be 'minimal' under a deal struck between...

What's coming up at the RCGP 2021 online conference - Dr David R Williams confirmed

What's coming up at the RCGP 2021 online conference - Dr David R Williams confirmed

The RCGP two-day virtual event takes place next month with keynote speaker Dr David...

GPs back BMA to lead talks on future of primary care networks

GPs back BMA to lead talks on future of primary care networks

GPs have voted for the BMA to continue to represent the profession in talks with...

COVID-19 vaccine deliveries paused in some areas to tackle 'geographical inequality'

COVID-19 vaccine deliveries paused in some areas to tackle 'geographical inequality'

Some GP-led vaccination sites will miss out on COVID-19 vaccine deliveries next week...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...